Company: BiPar Sciences
Based: Brisbane, CA
Amount: $37.5 million
Investors: Domain Associates, Quantum Technology Partners, Undisclosed Venture Firm, Vulcan Capital, Lighthouse Capital Partners, Canaan Partners,PolyTechnos Venture-Partners, Asset Management Company Venture Capital
Scoop: BiPar Sciences' lead product, BSI-201, is designed to enhance the anti-tumor effects of chemotherapy. BSI-201 is in Phase II clinical studies of patients with triple negative breast cancer, ovarian cancer and other malignancies. The company has two other drugs in pre-clinical development: BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and BSI-302, a novel anti-tubulin therapy. BiPar already raised an additional $20 million in January 2009 to continue its work.